Stratos Wealth Partners’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-4,536
| Closed | -$245K | – | 1458 |
|
|
2024
Q2 | $245K | Sell |
4,536
-412
| -8% | -$22.3K | ﹤0.01% | 1171 |
|
|
2024
Q1 | $337K | Sell |
4,948
-1,452
| -23% | -$99K | 0.01% | 1050 |
|
|
2023
Q4 | $401K | Buy |
6,400
+820
| +15% | +$51.3K | 0.01% | 955 |
|
|
2023
Q3 | $253K | Buy |
5,580
+1,226
| +28% | +$55.6K | 0.01% | 1084 |
|
|
2023
Q2 | $244K | Buy |
+4,354
| New | +$244K | 0.01% | 1030 |
|
|
2022
Q4 | – | Sell |
-3,784
| Closed | -$247K | – | 1148 |
|
|
2022
Q3 | $247K | Sell |
3,784
-167
| -4% | -$10.9K | 0.01% | 937 |
|
|
2022
Q2 | $240K | Sell |
3,951
-41
| -1% | -$2.49K | 0.01% | 1021 |
|
|
2022
Q1 | $251K | Buy |
3,992
+211
| +6% | +$13.3K | 0.01% | 1057 |
|
|
2021
Q4 | $287K | Buy |
3,781
+200
| +6% | +$15.2K | 0.01% | 1016 |
|
|
2021
Q3 | $401K | Buy |
3,581
+95
| +3% | +$10.6K | 0.01% | 837 |
|
|
2021
Q2 | $564K | Sell |
3,486
-652
| -16% | -$105K | 0.01% | 727 |
|
|
2021
Q1 | $504K | Sell |
4,138
-67
| -2% | -$8.16K | 0.01% | 719 |
|
|
2020
Q4 | $644K | Buy |
4,205
+670
| +19% | +$103K | 0.02% | 592 |
|
|
2020
Q3 | $296K | Sell |
3,535
-720
| -17% | -$60.3K | 0.01% | 791 |
|
|
2020
Q2 | $313K | Buy |
+4,255
| New | +$313K | 0.01% | 759 |
|
|
2020
Q1 | – | Sell |
-3,660
| Closed | -$223K | – | 938 |
|
|
2019
Q4 | $223K | Buy |
+3,660
| New | +$223K | 0.01% | 871 |
|
|
2018
Q4 | – | Sell |
-1,570
| Closed | -$70K | – | 1130 |
|
|
2018
Q3 | $70K | Buy |
+1,570
| New | +$70K | ﹤0.01% | 1296 |
|
|
2018
Q2 | – | Sell |
-465
| Closed | -$21K | – | 1279 |
|
|
2018
Q1 | $21K | Buy |
+465
| New | +$21K | ﹤0.01% | 1992 |
|